## Published Standard – No.1 – Applications (Centralised)

	Арр Туре	No. of Apps	Performance
1	Centralised: New MAs / Extensions	22	100%
2	Centralised – UK as Rapp: Variations / Renewals	8	87.5%

## Published Standard – No.1 – Applications (DCP)

	Арр Туре	No. of Apps	Performance
3	DCP – UK as RMS: New MAs & Variation-Extensions (Phase 1 – Day 70)	36	100%
4	DCP – UK as RMS: New MAs & Variation-Extensions (Phase 1 – Day 120)	51	100%
5	DCP – UK as RMS: New MAs & Variation-Extensions (Phase 2)	40	100%
6	DCP – UK as CMS: New MAs & Variation-Extensions (Phase 1)	78	98.7%
7	DCP – UK as CMS: New MAs & Variation-Extensions (Phase 2)	48	100%

# Published Standard – No.1 – Applications (MRP)

	Арр Туре	No. of Apps	Performance
8	MRP – UK as RMS: New MAs (Phase 1)	28	100%
9	MRP – UK as RMS: New MAs (Phase 2)	29	100%
10	MRP – UK as CMS: New MAs (Phase 2)	10	100%
11	MRP – UK as RMS: Type IA Variations	120	100%
12	MRP – UK as RMS: Type IB & II Variations, and Renewals (Phase 1)	196	100%
13	MRP – UK as CMS: Type IB & II Variations, and Renewals (Phase 1)	211	99.5%

	Арр Туре	No. of Apps	Performance
14	MRP – UK as RMS: Type IB & II Variations, and Renewals (Phase 2)	114	100%
15	MRP – UK as CMS: Type IB & II Variations, and Renewals (Phase 2)	170	100%

# Published Standard – No. 1 – Applications (National)

	Арр Туре	No of Apps	Performance	Target Days	Average Days
16	New MAs & Variation-Extensions: Initial Assessment	78	60%		
	75 Day Clock	4		75	70.5
	90 Day Clock	74		90	89.8
17	New MAs & Variation-Extensions Sign-Off	24	100%		
	• 130 Day Clock	2		130	83.0
	180 Day Clock	22		180	151.0
18	New Homeopathic	0	-	-	-
19	Type IA Variations	143	98.6%	30	21.5
20	Type IB / II Variations: Initial Assessment	140	99.3%		
	<ul> <li>Type IB</li> </ul>	75		30	15.7
	Type II	34		60	43.7
	Renewal	31		60	50.1
21	Type IB / II Variations: <i>Sign-Off</i>	135	99.3%		
	Type IB	72		30	3.4
	Type II	36		60	30.8
	Renewals	27		60	34.0
22	Admin Variations	25	100%		
	<ul> <li>&lt; 10 Changes</li> </ul>	25		30	23.9
	<ul> <li>&gt; 10 Changes</li> </ul>	0		60	-
23	ATCs	17	100%		
	• Type A/S	9		30	23.6
	• Туре В	7		50	32.4
	Variations / Renewals	1		30	29.0
24	Batch Release	3307	100%	10	0.7

	Арр Туре	No of Apps	Performance	Target Days	Average Days
25	<ul><li>Specific Batch Control</li><li>No questions asked</li><li>Questions asked</li></ul>	<b>125</b> 101 24	100%	10 20	3.3 13.3
26	AVA	4	100%	45	38.0

## Published Standard – No. 1 – Applications (Other)

	Арр Туре	No of Apps	Performance
27	Mock-Ups	548	99.5%
28	Validation	1094	99.9%
29	Issue of authorisation documentation	1278	99.6%

### Published Standard – No. 2 – Quality of Documentation

	Арр Туре	Total No	Performance
30	Authorisation Documentation	2394	97.7%

#### Published Standard – No. 3 – Import and Export Certificates

	Арр Туре	No of Apps	Performance	Target Days	Average Days
31	Applications for new products	232	98.3%	15	3.0
32	All other applications <ul> <li>Urgent</li> <li>Non-Urgent</li> </ul>	<b>418</b> 12 406	99.8%	2 10	1.0 2.0
33	Export	573	100%	10	4.7

### Published Standard – No. 4 – Public Assessment Reports

	Арр Туре	No of Apps	Performance	Target Days	Average Days
34	Publish link to SPC, or EMA	140	100%	30	2.0
35	Publish PuAR within 120 days	66	100%	120	77.0
36	Update PuAR within 60 days	114	99.2%	60	-

## Published Standard – No. 5 – Pharmacovigilance

	Task	No.	Performance
37	Human, Animal & Environmental AERs	6898	99.7%
38	Human, Animal & Environmental AERs – Follow Up	3519	99.9%
39	PSURs	1776	100%
40	Inspections	14	100%

## Published Standard – No. 6 – Inspections

	Task	No.	Performance	Target Days	Average Days
41	GMP Inspections within 3 years of last inspection	51	100%	-	-
42	GDP inspections within 5 years of last inspection	50	98.0%	-	-
43	Send deficiency or post inspections letter	106	100%		
	GMP	53		30	20.0
	• GDP	53		50	20.0
44	Issue GMP Certificates and final inspection reports	51	98.0%	90	71.0
45	Send final inspection report to wholesaler site	52	100%	90	71.0

## Key:

Dark Green -	Excellent 100%
Light Green -	Excellent, but some targets missed
Amber -	Effective
Red -	Ineffective